Biolidics shares sink 22% after calling off US sales of Covid-19 test kits
BIOLIDICS shares sank 22 per cent on Monday after the Catalist-listed firm announced on Sunday that it had mutually agreed with Aytu BioScience to terminate a distribution agreement for its Covid-19 antibody test kits in the US, amid increased competition for such kits. Shares of Biolidics, which ended Friday at 41 Singapore cents, plunged to 29.5 cents as at 8.58am on Monday. The stock recovered to 35 cents as at 9.26am, before closing at 32 cents, down nine cents. Earlier in April, Biolidics signed a one-year agreement with Aytu for the distribution of its test kits in the US after completing its US FDA listing. With the distribution deal scrapped, Biolidics will need to refund Aytu in full for all deposits paid with respect to undelivered orders of its test kits. The Catalist-listed company also intends to apply to voluntarily withdraw its application to the US Food and Drug Administration (FDA) for Emergency Use Authorisation (EUA) pursuant to the FDA's serology test po...